Cabaletta Bio

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Cabaletta Bio sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).

6 total trials 4 currently recruiting 1 completed early-phase tilt upper quartile by trial count

Cabaletta Bio: 6 sponsored US clinical trials, 4 recruiting.

Cabaletta Bio sponsors 6 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pemphigus Vulgaris, with 1 trials.

Upper-quartile sponsor footprint

Cabaletta Bio sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

6 total, page 1 of 1

RECRUITING Phase 1

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

NCT06328777
RECRUITING Phase 1

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

NCT06121297
RECRUITING Phase 2

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

NCT06154252
RECRUITING Phase 1

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

NCT04422912
ACTIVE NOT RECRUITING Phase 1

RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

NCT06359041
COMPLETED Phase 1

Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis

NCT05451212

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 1

Therapeutic Areas

Pemphigus Vulgaris 1
Generalized Myasthenia Gravis (gMG) 1
Juvenile Myositis 1
Juvenile Idiopathic Inflammatory Myopathy (JIIM) 1
Juvenile Polymyositis 1
Immune-Mediated Necrotizing Myopathy 1
Anti-Synthetase Syndrome 1
Idiopathic Inflammatory Myopathy 1
Systemic Sclerosis 1
Lupus Nephritis 1

What is open in the Cabaletta Bio pipeline

4 recruiting of 6 indexed (67% open); 1 completed (17%).

Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Pemphigus Vulgaris (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Cabaletta Bio: open-pipeline peers nationwide

Peers matched on 6 registered trials and 67% open enrollment, not the therapeutic-area sidebar.

Cabaletta Bio sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 234567 0%20%40%60%80% Total trials Recruiting share Cabaletta Bio23andMeAardvark TherapeuticsAbbisko Therapeutics CoAbGenomics B.V Taiwan BranchABL BioAccelerated Cure Project for Multiple SclerosisAdvanced Reconstructive Surgery AllianceAlexander B Olawaiye, MD
Cabaletta Bio sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Cabaletta Bio sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 6 trials (± recruiting share)

Sponsors near 67% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Cabaletta Bio page

6 registered trials is a research-attention snapshot, not an endorsement of Cabaletta Bio or any single study.

  • 4 of Cabaletta Bio's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Pemphigus Vulgaris is the condition Cabaletta Bio studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pemphigus Vulgaris trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Cabaletta Bio pipeline card: 6 registered trials from official public datasets.Report a data error.